Brent Sullivan, MD
Payments from drug & device makers
Across 41 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$169
- BD$108
- Johnson & Johnson$82
- Myovant Sciences Inc.$77
- AbbVie$77
- Endo Pharmaceuticals Inc.$61
- plus $294 from 11 others
What the payments were for
- Food & beverage$76788%
- Education$10012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $169 |
| BD | 5 | $108 |
| Johnson & Johnson | 4 | $82 |
| Myovant Sciences Inc. | 4 | $77 |
| AbbVie(2 entities) | 4 | $77 |
| Endo Pharmaceuticals Inc. | 3 | $61 |
| Rochester Medical Corporation | 2 | $52 |
| Isoray, Inc | 3 | $36 |
| Antares Pharma, Inc. | 2 | $33 |
| Pfizer | 2 | $33 |
| Boston Scientific | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Neotract Inc. | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Amgen | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$867 in reported general payments places this provider in the 20th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrelstarTriptorelin Pamoate | 19 | $48,517 |
| Tamsulosin Hcl | 248 | $3,274 |
| Bicalutamide | 62 | $2,525 |
| Dutasteride | 62 | $1,920 |
| Cefdinir | 140 | $1,626 |
| Finasteride | 147 | $1,524 |
| Estradiol | 19 | $1,336 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 20 | $565 |
| Ciprofloxacin Hcl | 91 | $532 |
| Levofloxacin | 67 | $311 |
| Tadalafil | 11 | $288 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $167 |
| Sildenafil Citrate | 26 | $159 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $109 |
| Oxybutynin Chloride | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Other urology in Tampa
- Osvaldo PadronTampa$1.3M
- Rafael CarrionTampa$445K
- Richard BrunelleTampa$357K
- Philippe SpiessTampa$304K
- Raviender BukkapatnamTampa$242K
- Alice YuTampa$181K
- David HernandezTampa$162K
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.